Blog

NEW YORK, NY / ACCESS Newswire / September 3, 2025 / For decades, the world has struggled to balance the economics of plastic waste with the urgency of sustainability. Policymakers imposed targets, companies pledged billions, and NGOs kept up the pressure. Yet the frameworks were never designed to succeed. Recycling programs focused narrowly on bottles and packaging while ignoring the much larger streams of industrial resins, automotive polymers, textiles, and electronics. The result was predictable: recycling rates stalled, incineration rose, and the promise of sustainable plastics remained an aspiration.

That is where SMX (NASDAQ:SMX) steps in. Its technology delivers what the UN Plastics Treaty has long placed on its wish list-replacing systems that failed with a platform that works. By tracking all categories of plastics, not just PET bottles or rPET packaging, SMX broadens the scope of recycling into entirely new markets. Dashboards can be made from recycled automotive polymers, electronics casings reborn from industrial resins, and textiles repurposed instead of burned. In short, every neglected stockpile and undervalued waste stream becomes a revenue opportunity, turning what was once written off into measurable value across the supply chain.

This shift is now moving from concept to reality. SMX and Singapore’s research agency ASTAR announced its mission to power the world’s first national plastics passport program. This is more than a compliance tool. By embedding molecular markers directly into materials, every kilogram of recycled plastic can now be verified, audited, and transformed into a financial instrument: the Plastic Cycle Token, or PCT.

SMX Makes Plastic a Bankable Asset
With that, SMX delivers material efficiency in its purest form. The proof isn’t a label on the outside of a product; it’s built inside. SMX’s patented molecular markers are embedded directly into plastics, metals, textiles, and natural rubber, giving every item a scannable, tamper-resistant identity tied to a verified digital passport. That link follows goods from origin through use, recycling, and even chemical transformation, proving recycled content, authenticity, and chain of custody in real time. The result is enforceable compliance, anti-counterfeiting, and true material efficiency that converts sustainability from promise to measurable value.

Unlike carbon credits, which have long battled accusations of opacity and double counting, PCTs are rooted in a tangible, physical trail. Each token corresponds to a verified unit of recycled plastic, giving it both accountability and tradability. This turns waste management into asset management. Recyclers can monetize output, brands can hedge their compliance exposure, and investors gain access to a new class of commodities tied directly to resource efficiency.

In a country like Singapore, the numbers are compelling. Redirecting just a third of today’s plastic waste into an SMX-verified loop could generate more than S$100 million annually in avoided incineration costs and new recycled resin value. For governments, this is fiscal efficiency. For brands, it’s proof. For markets, it’s an entirely new way of pricing sustainability.

What makes this moment transformative is not the technology alone, but the economic blueprint it creates. Across ASEAN, demand for post-consumer resin is surging, with premiums of 5% to 15% over virgin polymer already common in regulated sectors like automotive and electronics. As extended producer responsibility schemes tighten, verified supply will be worth even more. SMX’s model shows how supply chains can evolve from fragmented reporting systems into fully auditable markets, where sustainability is no longer a cost center but a profit driver.

Singapore’s program is historic on its own, but replicated regionally, the model unlocks an addressable market worth about S$4.2 billion annually in certified recycled materials and platform fees. The shift is clear: what once looked like a regulatory headache is now becoming a lever for competitiveness and growth.

SMX’s Defining Inflection Point
For SMX, this marks a shift from promise to proof. Years of pilots and R&D have culminated in the first national deployment of its platform. Singapore marks just the beginning. If this model spreads across ASEAN, SMX is positioned not only as a technology enabler, but as the architect of an entirely new marketplace.

The lesson here is simple: sustainability efforts fail when treated only as obligations. They succeed when they unlock new value. By converting plastics from environmental liabilities into verified financial assets, SMX is changing the conversation. Waste is no longer waste. It’s a resource with a measurable price, a tradable proof point, and a role in the next generation of global supply chains.

References

1. National Environment Agency (NEA). Waste & Recycling Statistics 2014 – 2023. Singapore: NEA; 2024.

2. Shunpoly.com. “How Much Plastic Is Wasted Each Year in Singapore?” Accessed 5 August 2025.

3. National Environment Agency (NEA). Waste-Statistics & Overall Recycling (interactive dashboard). Updated 2024; accessed 5 August 2025.

4. National Environment Agency (NEA). Mandatory Packaging Reporting portal. Accessed 5 August 2025.

5. Singapore Statutes Online. Environmental Public Health (Public Cleansing) Regulations – Incineration gate-fee schedule; revised 2024.

6. National Environment Agency (NEA). “New Licensing Regime for General Waste Disposal Facilities.” Technical brief & dialogue-session slides; 2024.

7. Nasdaq.com. “SMX Announces Planned Launch of World’s First Plastic Cycle Token.” Press release; 2024.

8. Yahoo! Finance. “SMX Plastic Cycle Token Is a Functional Market-Driven Solution…” News article; 2024.

9. Los Angeles Tribune. “Carbon Credits Had Their Day… Now the SMX Plastic Cycle Token…” Feature article; 2025.

10. National Environment Agency (NEA). Refuse Collection Fees for Households. Revised 2024; accessed 5 August 2025.

About SMX
As global businesses face new and complex challenges relating to carbon neutrality and meeting new governmental and regional regulations and standards, SMX is able to offer players along the value chain access to its marking, tracking, measuring and digital platform technology to transition more successfully to a low-carbon economy.

Forward-Looking Statements
The information in this press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intends,” “may,” “will,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this press release may include, for example: matters relating to the Company’s fight against abusive and possibly illegal trading tactics against the Company’s stock; successful launch and implementation of SMX’s joint projects with manufacturers and other supply chain participants of gold, steel, rubber and other materials; changes in SMX’s strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects and plans; SMX’s ability to develop and launch new products and services, including its planned Plastic Cycle Token; SMX’s ability to successfully and efficiently integrate future expansion plans and opportunities; SMX’s ability to grow its business in a cost-effective manner; SMX’s product development timeline and estimated research and development costs; the implementation, market acceptance and success of SMX’s business model; developments and projections relating to SMX’s competitors and industry; and SMX’s approach and goals with respect to technology. These forward-looking statements are based on information available as of the date of this press release, and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing views as of any subsequent date, and no obligation is undertaken to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. As a result of a number of known and unknown risks and uncertainties, actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include: the ability to maintain the listing of the Company’s shares on Nasdaq; changes in applicable laws or regulations; any lingering effects of the COVID-19 pandemic on SMX’s business; the ability to implement business plans, forecasts, and other expectations, and identify and realize additional opportunities; the risk of downturns and the possibility of rapid change in the highly competitive industry in which SMX operates; the risk that SMX and its current and future collaborators are unable to successfully develop and commercialize SMX’s products or services, or experience significant delays in doing so; the risk that the Company may never achieve or sustain profitability; the risk that the Company will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that the Company experiences difficulties in managing its growth and expanding operations; the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations; the risk that SMX is unable to secure or protect its intellectual property; the possibility that SMX may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties described in SMX’s filings from time to time with the Securities and Exchange Commission.

EMAIL: info@securitymattersltd.com

SOURCE: SMX (Security Matters) Public Limited

View the original press release on ACCESS Newswire

MIDLAND, MICHIGAN / ACCESS Newswire / September 3, 2025 / Chris and Casey Keefer, known worldwide as The Keefer Brothers, announce the launch of a digital basecamp, a new member-driven content hub and companion app that brings together adventure storytelling, skill-building courses, personal growth content, leadership lessons, and a proven mindset system for those seeking more out of life.

For 25 years, the Keefer Brothers have lived the life they share on screen, building brands, scaling businesses, producing award-winning content and television series, all while forging their approach to life in the most unforgiving environments. Enduring over 365+ days off-grid, they have developed a deep playbook of skills, strategies, and mindset frameworks that fuse raw outdoor roots with elite entrepreneurial execution.

The digital basecamp will serve as the home for:

• The Code: A Wilderness Forged Operating System for Life – A framework that blends hard-earned lessons from the wild with real-world strategies to help members push limits and thrive in modern life.

• Skill-Building Hunt Academy – In-depth, on-demand educational modules led by industry experts. The first course, Alaska DIY 101, distills 15 years of experience into a step-by-step guide for planning and executing a successful DIY Alaska hunt.

• Exclusive Hunting and Fishing Content – Behind-the-scenes footage, Dropped archives, and original film series like Generation Wild, a high adventure youth-focused collaboration with Bass Pro Shops and Cabela’s.

• Personal Growth Resources – Practical tools to apply wilderness lessons to daily life, relationships, and business.

• Community & Access – Member forums, live Q&As, challenges, and exclusive opportunities to connect directly with the Keefer Brothers.

• Contests and Experiences – Opportunities to win hunts, participate in skunkworks projects, gear-giveaways, and once-in-a-lifetime expeditions.

“We’ve built brands, survived off the land, and spent decades learning what it takes to thrive in high-stakes environments, in the wild and in business,” says Chris Keefer. “This content hub brings that experience together for people ready to challenge themselves and live a bigger story.”

This digital basecamp takes the Keefer Brothers’ mission beyond entertainment, creating a space where adventure fuels growth. Future plans include interactive experiences, exclusive gear drops, and collaborations with outdoor brands and creators.

“Our scars become your skills,” adds Casey Keefer. “The wild taught us to suffer with purpose, lead with grit, and live with fire. We’ve thrived in the toughest places on earth, but this is where we plant our flag for the future, for those ready to climb life’s second mountain and live a story worth telling.”

The Keefer Brothers’ digital basecamp is available now at www.keeferbrothers.com, with the companion app available on Apple and Google Play stores.

About The Keefer Brothers

Chris and Casey Keefer tell stories that sharpen, leading with proof rather than hype. For over 25 years the brothers have been successful entrepreneurs, hunters, anglers, guides, and storytellers. Their approach to life is built upon fire-tested leadership, faith-driven freedom and unapologetic self-reliance. They’re here to cultivate a mindset that outlives them. One that teaches the next generation to stand tall, hunt hard, lead well and never flinch at the unknown.

Media contact: media@keeferbrothers.com.

Contact Information

Keefer Brothers
media@keeferbrothers.com

SOURCE: BeAlive Inc

View the original press release on ACCESS Newswire

New capabilities across PRISM, SPG9000, INSPECT, and ARGUS deliver precision monitoring for broadcast, IP, and OTT services: See it in action at IBC2025

NEVADA CITY, CA / ACCESS Newswire / September 3, 2025 / Telestream, a global leader in media workflow technologies, will add powerful new capabilities to its Measurement portfolio at IBC2025, Stand 7.B21. These enhancements span Telestream’s PRISM waveform monitors, SPG9000 signal generators, INSPECT IP monitoring, ARGUS and the IQ family of probes, supporting next-generation deployments from live and remote production to post-production to multiplatform delivery.

Telestream’s Measurement solutions ensure confidence, precision, and actionable insight across the entire media creation, supply chain management, and distribution. The latest innovations demonstrate Telestream’s ongoing investment in helping media organizations manage complex workflows with precision, including ST 2110, HDR, SRT-based contribution, and multi-network observability.

“As media operations become more dynamic and decentralized, precision monitoring is more important than ever,” said Matthew Driscoll, VP of Product Management, Telestream. “At IBC2025, we’ll showcase the latest enhancements to our Measurement portfolio, designed to provide confidence, compliance, and actionable insights across the media supply chain. From SDI to IP transitions, remote and live production to OTT streaming, our solutions enhance signal integrity, simplify IP workflows, and advance HDR capabilities. With these innovations, Telestream continues to deliver precise monitoring and measurement for every workflow.“

Whether enabling distributed production teams to visualize contribution feeds, helping colorists perfect HDR content, or supporting broadcast engineers with real-time ST 2110 diagnostics, Telestream delivers the tools needed to maintain quality and performance in a rapidly evolving media ecosystem.

Key highlights of the Test and Measurement updates include:

• Timing and Signal Generation with SPG9000
  The SPG9000 introduces four-port PTP redundancy, in-band test signals, and dual-leader configurations for high-availability timing across IP, SDI, and hybrid systems. New features include ancillary test sequences, such as closed captions over both SDI and ST 2110-40. This enhances commissioning workflows and compliance checks.

See Telestream at IBC2025
Telestream will showcase new Test and Measurement solutions at IBC2025 at Stand 7.B21. To schedule a meeting or request a demonstration, visit https://www.telestream.net/ibc2025/#schedule-a-meeting-section.

Download press imagery here.

About Telestream
Ingest. Enhance. Deliver.

Telestream has been at the forefront of digital media innovation for nearly three decades, serving as the trusted partner behind some of the world’s most mission-critical media operations. Its industry-leading test and measurement and media workflow solutions streamline operations and scale efficiently across the entire media lifecycle-from capture and live production to automation, processing, quality control, content management, and distribution. Designed for on-premises, cloud, and hybrid environments, Telestream ensures high-quality media delivery to any audience, on any platform. The company is privately held and headquartered in Nevada City, California. Learn more at www.telestream.net.

Press Contact

Kristin Canders
Grithaus Agency
(e) kristin@grithaus.agency
(p) +1 (207) 974-7744

####

SOURCE: Telestream LLC

View the original press release on ACCESS Newswire

LOS ANGELES, CALIFORNIA / ACCESS Newswire / September 3, 2025 / Venerable independent genre film distributor Full Moon’s first collaboration with successful vertical media app ReelShort, the Charles Band produced and directed DUNGEONS OF ECSTASY, has already reached an impressive viewership of nearly three million streamers since its Sept. 1 premiere. The erotic, dramatic thriller (the first vertical entertainment to be filmed in Italy) stars ReelShort/vertical media superstars Nicole Mattox and Eric Guillmette, along with Felix Merback, (who also serves as an executive producer) and has been getting rave reviews from ReelShort fans and subscribers, with many of them calling it “Hot,” “Bold” and “Unforgettable.”

Synopsis: After a near-fatal car crash shatters her body and breaks her spirit, journalist Emily [Mattox] escapes to a remote rural region of Italy, only to find herself ensnared in the mysterious and forbidden “Dungeons of Ecstasy.” Here, in the darkest chambers of the dungeon, Emily’s captor – who uncannily resembles her long lost ex-husband – forces her through a series of dangerous, sensual trials that awaken taboo memories and a love she’s never known.

DUNGEONS OF ECSTASY is available now exclusively through the ReelShort app as a sexy, cling-hanging 61 episode series. An extended, alternate version will be available as a fully edited feature on the Full Moon Features streaming channel as well as Amazon Prime at a later date. The vertical media format has taken the streaming entertainment universe by storm. A recent article in The Washington Post claimed that the popularity of platforms like ReelShort rests in the fact that these “mini-dramas combine the adrenaline-fueled rhythm of TikTok with the familiarity of a romance novel” – and DUNGEONS OF ECSTASY is no exception. The series has also been making waves in genre film publications like JoBlo.com and Rue Morgue, making Full Moon’s first foray into the medium a groundbreaking out-of-the-box success.

Watch the DUNGEONS OF ECSTASY trailer here, watch the film here, and be sure to follow the ReelShort universe on Instagram here.

SOURCE: Full Moon Empire, Inc.

View the original press release on ACCESS Newswire

ORLANDO, FL / ACCESS Newswire / September 3, 2025 / OGRD Alliance introduces PLPC-DB™, a next-generation, non-cellular oncology immunotherapy platform now entering a global acquisition window. Unlike cell- or gene-based products, PLPC-DB™ is a lyophilized phospholipoproteic complex stable for more than 18 months at room temperature, eliminating cold-chain dependency and reducing infrastructure costs by over 60%. The platform is anchored in the Structured Immunophenotypic Traceability Platform (STIP), recently enhanced with a Network Access Module (NAM), ensuring auditable immune fingerprinting.

Unlike cell- or gene-based products, PLPC-DB™ is a lyophilized phospholipoproteic complex stable for more than 18 months at room temperature. This eliminates cold-chain dependency and reduces infrastructure costs by over 60%, offering a scalable and sustainable option for oncology innovation.

Scientific and Regulatory Foundation

PLPC-DB™ is anchored in the Structured Immunophenotypic Traceability Platform (STIP), enhanced with a Network Access Module (NAM). This proprietary framework ensures interoperability and auditability of immune fingerprints, inter-batch consistency, and reproducibility across jurisdictions.

More than a decade of structured patient monitoring through the OncoVix™ program in Latin America supported the validation of STIP-NAM. By documenting outcomes in a standardized, transferable format, the system provides proportional validation without requiring sequential Phase I-III trials.

Independent regulatory consultancies have confirmed dossier maturity for FDA-facing discussions. This structure secures a valuation floor at USD 350M+, with upside >USD 600M following FDA filing (~2×) and >USD 1B under favorable Written Response Only outcomes (~3×).

Scientific Differentiation

PLPC-DB™ coordinates innate and adaptive immune responses, enhancing NK and CD8⁺ effector activity and CD4⁺ Th1 polarization. It improves antigen presentation (MHC I/II → CD8⁺/CD4⁺) and reduces inhibitory cytokines such as IL-10 and TGF-β, reprogramming the tumor microenvironment.

These findings are supported by five PubMed-indexed Q1 publications and eleven Tier-1 oncology congress presentations. The program is directed by Dr. Ramón Gutiérrez-Sandoval M.D., oncopathologist and Chief Scientific Officer of OGRD Alliance.

Market Significance

The global oncology immunotherapy market exceeds USD 120B, with ~10% CAGR. PLPC-DB™ addresses cost and scalability barriers through:

• Operational efficiency: shelf-stable, non-replicative formulation.

• Access models: hospital-based and supervised at-home protocols.

• Sustainability: aligned with UN Agenda 2030 and Vision 2030, reducing environmental and logistical burdens.

Unique Investment Profile

PLPC-DB™ is positioned as a de-risked pre-FDA asset, supported by regulatory validations, multiple publications, and a three-continent patent family with a 240-file trade-secret archive. It is structured for rapid valuation inflection once FDA milestones are achieved.

Global Licensing and Acquisition Window

PLPC-DB™ is currently in a preferential pre-sale phase open to qualified stakeholders. Following this stage, structured territorial licensing or regional alliances may be introduced.

Acquisition Options: OGRD Alliance confirms that both 80% and 100% ownership stakes are available for immediate transfer, subject to due diligence and binding agreements.

Links

• Official site: www.PLPC-DB.com

• PubMed Publications – OGRD Alliance: https://pubmed.ncbi.nlm.nih.gov/?term=ogrd+alliance

• Official video overview: https://youtu.be/28D_c1yQziY

Media Contact: press@plpc-db.com

Disclaimer: PLPC-DB™ remains investigational. This release is for informational purposes only and refers exclusively to scientific findings, regulatory documentation, and investment opportunities. No therapeutic claims are being made.

SOURCE: OGRD Alliance

View the original press release on ACCESS Newswire

BRUSSELS, BE / ACCESS Newswire / September 3, 2025 / Mediagenix, a global leader in smart content solutions to profitably connect the right content to the right audience, today announced the appointment of Tim Goff as Vice President of Curation and Scheduling. With over 20 years of experience delivering large-scale transformations across media, broadcast, and digital platforms, Goff brings deep expertise in operational excellence, content strategy, and workflow innovation. He has held technology leadership roles at Peloton, UKTV, and the BBC, where he led cross-functional global teams, managed multi-million-pound programmes, and introduced game-changing content workflows.

“Tim’s appointment is an important step in our mission to deliver the most robust and forward-looking solutions for content owners worldwide,” said Emmanuel Muller, Chief Product Officer at Mediagenix. “Curation and scheduling sit at the heart of the media operation and represent the greatest opportunity for companies to optimise efficiencies and maximise ROI. Tim’s strategic approach and proven hands-on operational know-how will help our customers optimise their businesses in ways that are both profitable and transformational.”

With Goff joining the team, Mediagenix gains practical insight into the challenges broadcasters face when deploying cloud and software-based live production at scale, bringing revenue-impacting insights that further validate the strength of Mediagenix leadership in strategic content operations.

“I’m thrilled to join Mediagenix and lead this key solution offering,” said Goff. “It is an exciting opportunity to help shape the next chapter of curation and scheduling innovation with a team that’s redefining how the industry approaches content strategy. I’m especially looking forward to working with Emmanuel Muller and the talented colleagues across Mediagenix to deliver real, measurable value for our customers.”

Meet Tim Goff at IBC2025

Tim will be attending IBC2025, where Mediagenix will showcase the full integration of Spideo’s advanced personalization and recommendation capabilities across the Mediagenix solution suite, delivering measurable gains in content engagement, monetization, and operational agility.

“IBC is the ideal opportunity to connect with customers and show how curation and scheduling can be transformed with audience intelligence that runs across the entire content lifecycle,” Goff added. “With Spideo fully integrated into the Mediagenix platform, we can help media companies make sharper, faster decisions about what content to produce, acquire and schedule, unlocking new levels of engagement and monetization.”

Mediagenix was recently recognized as an IDC Innovator in the IDC Innovators: Media and Entertainment 2025* for its breakthrough approach to embedding personalization across the content lifecycle.

Visit Mediagenix at IBC2025 in Hall 1, Stand 1.B57. To book a meeting, please visit: https://www.mediagenix.tv/event/ibc-2025/

*Recently, Mediagenix was named an IDC Innovator in the IDC Innovators: Media and Entertainment, 2025 (doc #US52275525, May 2025) report.

About Mediagenix

Mediagenix is a global leader in smart content solutions to profitably connect the right content to the right audience. The Mediagenix modular SaaS platform orchestrates the entire content lifecycle to actively drive content lifetime value and audience engagement. Content strategy, content value management, content scheduling and content personalization all converge into one lean, company-wide collaborative flow revolving around one source of truth. Headquartered in Brussels, Mediagenix has offices in Bangkok, Denver, London, Madrid, Miami, New York City, Paris, Singapore, Skopje, and Sydney. With a team of 400+ experts working closely with 10,000+ users, Mediagenix is the trusted partner for more than 200 media companies globally.

Press Contact

Melissa Harding
Grithaus Agency
(e) melissa@grithaus.agency
(p) +44 7594 079738

####

SOURCE: Mediagenix

View the original press release on ACCESS Newswire

• Aspire’s sublingual aspirin formulation significantly inhibited serum thromboxane B2 (TxB2) within the first two minutes after dosing

• TxB2 is a biomarker indicating aspirin’s effect on platelet aggregation, the clumping of platelets that leads to dangerous blood clots

• This rapid inhibition is critical during suspected heart attacks, when clots blocking heart arteries can cause permanent muscle damage

• Lab results showed Aspire’s product acted approximately twice as fast as the current recommendation for chewed aspirin tablet treatment

• These clinical trial results enable a potential regulatory submission for accelerated approval on track for Q3 2025

ESTERO, FLORIDA / ACCESS Newswire / September 3, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) (“Aspire” or the “Company”), developer of a multi-faceted patent-pending drug delivery technology, today announced positive final results from its randomized, crossover bioavailability trial to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of Aspire’s investigational new sublingual aspirin product compared to chewed uncoated aspirin tablets in healthy adults. The final results demonstrated that Aspire’s sublingual aspirin product produced higher and more rapid mean plasma concentrations of acetylsalicylic acid (ASA, the active antiplatelet form of aspirin) compared to chewed aspirin tablets (p0.05), as detailed in Aspire’s previous press release. The product was also safe and well-tolerated by patients, and no adverse events were reported. However, even more clinically significant results were discovered since the press release announcing top-line results was issued on August 18, 2025.

Important New Findings

Aspire’s OTASA BA2039 sublingual formulation also significantly inhibited serum thromboxane B₂ (TxB₂) within the first two minutes after dosing compared to the chewed oral aspirin tablets (p0.02). TxB₂ is a biomarker for the effect of aspirin on platelet aggregation. This has significant and important positive implications for its role in the inhibition of blood clotting and its role in heart attacks.

These important results underscore the potential of Aspire’s sublingual aspirin product to be the market-leading treatment for suspected acute myocardial infarction (AMI, blockage of blood flow to heart muscle causing damage or death of heart tissue – commonly known as a “heart attack”). There are an estimated 18 million Americans living with coronary artery disease with approximately 800,000 per year experiencing an AMI leading to 300,000 deaths.

According to a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines dated April 1, 2025, “Aspirin has long been considered an integral part of anti-platelet therapy to prevent recurrent atherothrombotic events among patients with Acute Coronary Syndromes (ACS). Aspirin reduces the incidence of vascular death after AMI, and in secondary prevention trials (that include patients after MI), it re-duces the occurrence of vascular and coronary events, including MI and stroke.

Aspirin should be initiated with a loading dose (162-325 mg) in patients with ACS without an absolute contraindication as soon as possible on presentation irrespective of final management strategy (invasive or noninvasive).” Aspire’s sublingual product rapidly delivers 162.5 mg of aspirin, precisely in the range suggested by this study, and Aspire’s product begins to show TxB2 inhibition in two minutes or less.”

Kraig Higginson, Interim Chief Executive Officer of Aspire, commented, “The final results from our recent clinical trial confirm our belief that our high dose sublingual aspirin has to the potential to be a life-changing, market-leading treatment for patients experiencing a suspected heart attack. Patients in our study experienced a significantly improved time of inhibition of TxB₂, a biomarker for platelet aggregation, the process where activated platelets stick to each other to block the flow of blood to heart muscle. We believe our new sublingually delivered aspirin has the potential to save lives. We look forward to presenting these data to the FDA as we move down the development pathway towards potential commercialization of our safe, novel and effective sublingual form of high dose aspirin. We hope the day will soon come that every EMT, emergency service provider, and hospital will have our sublingual aspirin on hand for those suffering from heart attacks.”

* TxB₂ is a stable metabolite of thromboxane A₂ (TxA₂), a potent chemical that promotes platelet clumping and vasoconstriction. Measuring low levels of TxB₂ confirms that aspirin is working as intended.

The results of Aspire’s clinical study suggest that sublingual administration of aspirin provides earlier drug exposure and platelet inhibition than the current standard-of-care, which is chewing and swallowing uncoated aspirin tablets. Numerous published studies indicate that an even more rapid pharmacodynamic effect would be desirable during the early phase of thrombus evolution in the setting of myocardial infarction or ischemic stroke (i.e., the sooner TxB2 concentration can be reduced, the better for the patient). Reducing mean serum TxB₂ concentration after aspirin dosing-which the clinical study demonstrates that Aspire’s sublingual aspirin product does rapidly, starting in 2 minutes or less–indicates successful inhibition of platelet aggregation, which may reduce the risk of vascular death and other major adverse cardiovascular events.

Advancing Aspire’s Sublingual Aspirin

Aspire plans to review its clinical trial results with the U.S. Food and Drug Administration (FDA) to enable a potential regulatory submission for accelerated approval in the third quarter of 2025.

About Aspire’s Clinical trial AB-101

Clinical trial AB-101 was a randomized crossover bioavailability study of Aspire’s investigational new sublingual aspirin product compared to chewed uncoated aspirin tablets. Six otherwise healthy 40 to 65-year-old subjects were administered 162 mg aspirin as a single dose in each of three treatment periods separated by two 14-day washout periods. Two different investigational sublingual powder and granule formulations (Aspire Biopharma) and chewed uncoated oral aspirin tablets (Bayer) were studied. The primary objective of the clinical trial was to evaluate the bioavailability of ASA in plasma over eight hours after dosing. An additional objective was to evaluate the potentially life-saving effect of each treatment on serum TxB₂.

Aspire’s sublingual aspirin is an investigational new drug and has not been approved for marketing by FDA or any other government regulatory authority.

About Oral Aspirin

Oral aspirin is FDA-approved for treatment of suspected AMI with the initial dose of 160-162.5 mg is administered as soon as an AMI is suspected.ⁱ In a large, multicenter study of aspirin, streptokinase, and the combination of aspirin and streptokinase in 17,187 patients with suspected AMI, aspirin treatment produced a 23 percent reduction in the risk of death from cardiovascular diseases within five weeks.ⁱⁱ Clinical practice guidelines recommend that aspirin be initiated as soon as possible with the initial dose chewed, when possible, to achieve faster onset of antiplatelet action.ⁱⁱⁱ

About Aspire Biopharma Holdings, Inc.

Aspire Biopharma has developed a patent-pending sublingual delivery technology that can deliver drugs to the body rapidly and precisely. This technology offers the potential to improve effectiveness and reduce side effects by going directly to the bloodstream and avoiding the gastrointestinal tract. Aspire Biopharma’s delivery technology can be applied to many different active pharmaceutical ingredients (APIs) and other bioactive substances, spanning both small and large molecule therapeutics, nutraceuticals and supplements.

For more information, please visit www.aspirebiolabs.com

Safe Harbor Statement

This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the “safe harbor” provisions created by those laws. Aspire’s forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would,” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug candidates, if approved; our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our drug candidates; and other risks and uncertainties set forth in “Risk Factors” in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.

View the original press release on ACCESS Newswire

An inspiring day of connection, learning, and impact.

CHARLOTTE, NORTH CAROLINA / ACCESS Newswire / September 3, 2025 / Mental Health America of Central Carolinas (MHACC) is proud to announce that Nora McInerny, bestselling author, award-winning podcast host, and internationally recognized speaker, will deliver the keynote address at the Southeast Regional Conference on Mental Health, taking place Thursday, October 30, 2025, at the UNC Charlotte Marriott Hotel & Conference Center.

McInerny is best known for her celebrated books (It’s Okay to Laugh, No Happy Endings, Bad Vibes Only) and as the host of the widely acclaimed podcast Terrible, Thanks for Asking, which blends humor, honesty, and hope to explore some of life’s most difficult topics. Her keynote will inspire attendees with her trademark mix of vulnerability and levity, encouraging open conversations about grief, resilience, and mental wellness.

“Having Nora McInerny join us as our keynote speaker is an incredible honor,” said Ayo Johnson, Executive Director of MHACC. “Her ability to connect with audiences, break down stigma, and make space for the full spectrum of human experiences aligns perfectly with the vision for this inaugural conference.”

About the Conference

The Southeast Regional Conference on Mental Health will bring together mental health professionals, advocates, and community leaders for a day of learning and connection. Sessions will focus on three core areas:

• Advocacy: Policies and practices shaping mental health equity.

• Education: Clinical insights, community learning, and public awareness.

• Access: Strategies to expand access to care across diverse populations.

Event Details

• What: Southeast Regional Conference on Mental Health

• When: Thursday, October 30, 2025

• Where: UNC Charlotte Marriott Hotel & Conference Center

• Registration: mhaofcc.org/conference

About Mental Health America of Central Carolinas

Mental Health America of Central Carolinas has served the region for over 90 years, providing education, advocacy, and direct support services to families and individuals. Programs include family support for parents of children with behavioral and mental health needs, peer support for adults, free counseling for those who cannot afford care, and mental health education for the broader community. Learn more at mhaofcc.org.

Contact Information

J. Hill
Public Relations Manager
jhill@branduscriptpr.com
704-287-6998

SOURCE: The Branduscript Agency

View the original press release on ACCESS Newswire